KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GSK) Equity Income (2016 - 2025)

Historic Equity Income for Gsk (GSK) over the last 9 years, with Q3 2025 value amounting to $5.4 million.

  • Gsk's Equity Income rose 51531.52% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 million, marking a year-over-year increase of 7586.93%. This contributed to the annual value of -$3.8 million for FY2024, which is 3833.81% up from last year.
  • As of Q3 2025, Gsk's Equity Income stood at $5.4 million, which was up 51531.52% from -$2.7 million recorded in Q2 2025.
  • In the past 5 years, Gsk's Equity Income ranged from a high of $5.4 million in Q3 2025 and a low of -$6.2 million during Q4 2023
  • Moreover, its 4-year median value for Equity Income was -$2.3 million (2022), whereas its average is -$1.8 million.
  • Its Equity Income has fluctuated over the past 5 years, first crashed by 16454.13% in 2023, then surged by 51531.52% in 2025.
  • Gsk's Equity Income (Quarter) stood at -$2.3 million in 2022, then plummeted by 164.54% to -$6.2 million in 2023, then skyrocketed by 37.95% to -$3.9 million in 2024, then surged by 240.14% to $5.4 million in 2025.
  • Its Equity Income was $5.4 million in Q3 2025, compared to -$2.7 million in Q2 2025 and -$3.9 million in Q4 2024.